EP0662839A4 - Impfstoff und Antigenkonjugate. - Google Patents

Impfstoff und Antigenkonjugate.

Info

Publication number
EP0662839A4
EP0662839A4 EP92921753A EP92921753A EP0662839A4 EP 0662839 A4 EP0662839 A4 EP 0662839A4 EP 92921753 A EP92921753 A EP 92921753A EP 92921753 A EP92921753 A EP 92921753A EP 0662839 A4 EP0662839 A4 EP 0662839A4
Authority
EP
European Patent Office
Prior art keywords
hormone
fragment
epitope
immunologically equivalent
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92921753A
Other languages
English (en)
French (fr)
Other versions
EP0662839A1 (de
Inventor
Vernon C Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Priority to EP01102609A priority Critical patent/EP1129724B1/de
Priority to DE69233711T priority patent/DE69233711D1/de
Publication of EP0662839A1 publication Critical patent/EP0662839A1/de
Publication of EP0662839A4 publication Critical patent/EP0662839A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP92921753A 1992-09-30 1992-09-30 Impfstoff und Antigenkonjugate. Ceased EP0662839A4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01102609A EP1129724B1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs
DE69233711T DE69233711D1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/008370 WO1994007530A1 (en) 1992-09-30 1992-09-30 Vaccines and antigenic conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01102609A Division EP1129724B1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs

Publications (2)

Publication Number Publication Date
EP0662839A1 EP0662839A1 (de) 1995-07-19
EP0662839A4 true EP0662839A4 (de) 1995-09-06

Family

ID=25677857

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92921753A Ceased EP0662839A4 (de) 1992-09-30 1992-09-30 Impfstoff und Antigenkonjugate.
EP01102609A Expired - Lifetime EP1129724B1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01102609A Expired - Lifetime EP1129724B1 (de) 1992-09-30 1992-09-30 Impfstoffe zur Behandlung von Kolonkrebs

Country Status (7)

Country Link
EP (2) EP0662839A4 (de)
JP (1) JPH08502062A (de)
AT (1) ATE373486T1 (de)
AU (1) AU679902B2 (de)
CA (1) CA2145391A1 (de)
DE (1) DE69233711D1 (de)
WO (1) WO1994007530A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
JP2002534478A (ja) * 1998-12-18 2002-10-15 エイブイアイ バイオファーマ， インコーポレイテッド 絨毛性ゴナドトロピンｄｎａワクチンおよび方法
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
EP1372717A2 (de) 2001-03-23 2004-01-02 Aphton Corporation Kombinationsbehandlung von pankreaskrebs
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
WO2004088326A2 (en) 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
CN101048659B (zh) 2004-09-22 2013-03-13 受体生物技术公司 抗前胃泌素单克隆抗体
WO2006081826A2 (en) * 2005-02-04 2006-08-10 Survac Aps Survivin peptide vaccine
EP1912680B1 (de) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2-peptide
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
WO2011056226A1 (en) * 2009-11-05 2011-05-12 Mercia Pharma Llc Adjuvanted nanoparticulate influenza vaccine
KR20200015943A (ko) 2017-06-15 2020-02-13 캔설 어드밴스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000107A1 (fr) * 1989-07-03 1991-01-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
EP0427347A1 (de) * 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetische Peptide nützlich als universale Träger für die Herstellung von immunogenischen Konjugaten und deren Benützung in der Entwicklung von synthetischen Impfstoffen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006334A (en) * 1973-05-07 1991-04-09 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4762913A (en) * 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4310455A (en) * 1979-04-17 1982-01-12 Research Corporation Antigen for early pregnancy test and contraceptive vaccine
US4855285A (en) * 1985-12-04 1989-08-08 The Ohio State University Research Foundation Antigenic modification of polypeptides
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000107A1 (fr) * 1989-07-03 1991-01-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
EP0427347A1 (de) * 1989-11-10 1991-05-15 ENIRICERCHE S.p.A. Synthetische Peptide nützlich als universale Träger für die Herstellung von immunogenischen Konjugaten und deren Benützung in der Entwicklung von synthetischen Impfstoffen

Also Published As

Publication number Publication date
EP1129724B1 (de) 2007-09-19
WO1994007530A1 (en) 1994-04-14
JPH08502062A (ja) 1996-03-05
EP0662839A1 (de) 1995-07-19
EP1129724A3 (de) 2001-11-07
AU679902B2 (en) 1997-07-17
DE69233711D1 (de) 2007-10-31
AU2806392A (en) 1994-04-26
CA2145391A1 (en) 1994-04-14
ATE373486T1 (de) 2007-10-15
EP1129724A2 (de) 2001-09-05

Similar Documents

Publication Publication Date Title
EP0662839A4 (de) Impfstoff und Antigenkonjugate.
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
AUPP807399A0 (en) Improved immunogenic lhrh composition and methods relating thereto
HUT72193A (en) Ganglioside-klh conjugate vaccines with qs-21
DE3380053D1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them
EP0716613A4 (de) BEHANDLUNG EINES DURCH -i(HELICOBAKTER PYLORI) VERURSACHTEN GASTRODUODENALEN KRANKHEIT
AU6714290A (en) Method of treating infectious bursal disease virus
DE69333448D1 (en) P53 impfstoff
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
EP0881910A4 (de) Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
GR3019356T3 (en) Recombinant mycoplasma hyopneumoniae antigen and uses therefor
GR3029727T3 (en) Synthetic peptides and vaccines against parvovirus.
EP0282501A1 (de) Regulierung der tierreproduktion
GR3036369T3 (en) Vaccines based on streptokinase.
PT101264A (pt) Dispositivo de vacinacao de coelhos por via parenterica contra a enterotoxemia do coelho e vacina a base de anotoxina de clostridium spiroforme condicionada para utilizacao nesse dispositivo
DE69322960T2 (de) Empfängnisverhütender impfstoff
EP0502100A4 (en) Reduced-protein subunit vaccine for swine dysentery
de Pilar Antibodies for developing adolescents and children. Conclusions for vaccinations against rubella, measles, mumps, diphtheria and tetanus.).
DE69012328D1 (de) Srif-verwandte peptide und deren verwendungen.
MX9700215A (es) Proteinas y vacunas de helicobacter.
SE8400934L (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 39/00

17Q First examination report despatched

Effective date: 19961104

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19980507

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE